Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Symbios Announces Two National Institutes of Health SBIR Phase I Awards for Plasma Oxidation Technology
  • USA - English


News provided by

Symbios Technologies

Nov 17, 2016, 10:50 ET

Share this article

Share toX

Share this article

Share toX


The formation of plasma species within aqueous solutions sets Symbios TPR-generated chemotherapeutics apart from other plasma-based technologies

Post this

Fort Collins, Colorado (PRWEB) November 17, 2016 -- Symbios Technologies, Inc., a world-leading developer of dynamic aqueous plasma technology platforms, announced today that the National Cancer Institute (NCI) and the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) have awarded the company Small Business Innovation Research (SBIR) Phase I grants totaling $449,931. The funds will be used to develop innovative uses of plasma technology to create safer, more effective chemotherapeutic solutions for difficult to treat cancers, such as pancreatic cancer, and anti-infective products for the treatment of a wide range of microbial contaminants associated with hospital acquired infections (HAI) and wound recovery.

The “Plasma Generation of Aqueous Chemotherapeutic Solutions” project, NIH National Cancer Institute Award Number R43CA203273, will use the Symbios Tubular Plasma Reactor™ (TPR) platform to generate chemotherapeutic solutions through a low-temperature plasma discharge. This promising new method for selectively killing cancer cells is unique in generating plasma-based chemotherapeutics within aqueous solutions and allows clinicians multiple routes of administration of the solution to the cancerous site.

The “Continuous Production of Organic Peroxyacid Microbial Agents for Wound Care Using a Selective Plasma Oxidation Reactor” project, NIH National Institute of General Medical Sciences Award Number R43GM121092, will utilize Symbios plasma technology as an alternate manufacturing platform to help enable the safe and more cost-effective mass production of anti-infective healthcare products. Specifically, Symbios is collaborating with CHD Bioscience, Inc. (CHD) to develop an alternative high volume production method for CHD’s flagship product, VERIOX™. VERIOX is a proprietary blend of peroxyacid compounds which has shown great promise as an anti-infective and wound-healing healthcare product.

Both projects are being led by Principal Investigator Jessica Joslin, PhD., Senior Scientist at Symbios. Working in the Therapeutic Materials and Biointerfacial Research Laboratory at Colorado State University, Dr. Joslin previously developed methods for characterizing polymeric biomaterials with the ability to release the bio-agent, nitric oxide.

“The TPR platform enables the environmentally friendly production of aqueous plasma chemotherapeutic (APC) solutions,” said Dr. Joslin. “This can allow us the ability to provide selective and dose-dependent cancer cell growth inhibition to address critical cancer therapy needs. The formation of plasma species within aqueous solutions sets TPR-generated APC apart from other plasma-based technologies.”

“In addition, the groundbreaking design of the TPR also allows us the ability to tune its operating parameters and use low-energy plasma discharge in a continuous flow process. This capability will help CHD dial in the right amount of peroxyacid compounds to cost effectively produce VERIOX,” continued Dr. Joslin.

“Collaboration is a critical success factor for all innovative companies,” concluded Brooks Hybertson, PhD, Vice President, R&D at Symbios and Co-Investigator on both grants. “We are grateful to both the NCI and the NIGMS for selecting Symbios as an SBIR award recipient for these important and potentially lifesaving projects and the opportunity to work with a transformative company like CHD and other industry partners that are helping us drive Symbios technology forward.”

Research reported in this publication was supported by the National Institute of General Medical Sciences and the National Cancer Institute of the National Institutes of Health under Award Number R43GM121092 and R43CA203273, respectively. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Symbios Technologies

Symbios Technologies, Inc. is a world-leading developer of dynamic aqueous plasma technology platforms for water treatment, specialty manufacturing, and biotherapeutic applications. The company, working with its university, government, and industrial partners is commercializing its disruptive advanced low-cost aqueous plasma oxidation technology, the Symbios Tubular Plasma Reactor™ (TPR4000™), to clean water, preserve the environment, and protect human health while improving production economics and sustainability. Symbios Technologies’ modular reactor is low in capital cost, able to replace existing energy-hungry or poor-performing advanced oxidation processes, while reducing or eliminating the use of biocides and/or chemical additives, thus improving the overall maintenance cost of water treatment systems, in particular extending the life and reducing fouling of membranes. For more information, go to http://www.symbiosplasma.com/.

About the National Institutes of Health (NIH)

NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

About NCI

NCI leads the National Cancer Program and the NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER.

About NIGMS

The National Institute of General Medical Sciences (NIGMS) supports basic research that increases understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS-funded scientists investigate how living systems work at a range of levels, from molecules and cells to tissues, whole organisms, and populations. The Institute also supports research in certain clinical areas, primarily those that affect multiple organ systems. To assure the vitality and continued productivity of the research enterprise, NIGMS provides leadership in training the next generation of scientists, in enhancing the diversity of the scientific workforce, and in developing research capacities throughout the country.

Justin Bzdek, Symbios Technologies, http://www.symbiostechnologies.com, +1 970-492-4418, [email protected]

Modal title

Symbios TPR4000
View PDF
Symbios TPR4000
Symbios TPR Plasma on - Plasma Off
Symbios TPR Plasma on - Plasma Off
Symbios TPR4000 Symbios TPR Plasma on - Plasma Off

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.